Real-World Pharmacoeconomic Assessment of Paliperidone Palmitate for Schizophrenia Management:A Retrospective Analysis

Author:

Zhou Yixiang1,Chen Binbin1,Huang Yinghua1

Affiliation:

1. Xiamen Xianyue Hospital

Abstract

Abstract Background: To perform a pharmacoeconomic assessment of one-year maintenance treatment in stable schizophrenic patients with paliperidone extended-release tablets (PPER) and paliperidone palmitate once-monthly (PP1M) and provide a reference for clinicians in patient selection. Methods: A retrospective investigation and analysis were conducted on stable schizophrenic patients who had been on PPER or PP1M for at least one year between June 2014 and December 2019. Patient demographic data, direct medical and nonmedical costs, and other information were collected. The clinical efficacy data were obtained from published articles, and a cost-effectiveness analysis was conducted. Results:The PPER and PP1M groups included data from 84 and 62 patients, respectively. The two groups had no significant difference in gender and age. The total effective rates of PPER and PP1M were 73.17 and 97.37%, respectively. The registration frequency in the PPER group was significantly higher than that in the PP1M group (P <0.001). The cost of medication and total treatment was significantly higher in the PP1M group than in the PPER group (P <0.001). The cost/effect value was slightly higher in the PP1M group than in the PPER group. The incremental cost-effect ratio of both treatments was 369.07 yuan, less than the per capita gross domestic product (GDP) value. Conclusion: Both formulations of paliperidone were found to be suitable for the long-term management of schizophrenia, while PP1M has better pharmacoeconomic advantages.

Publisher

Research Square Platform LLC

Reference30 articles.

1. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019;GBD 2019 Mental Disorders Collaborators;Lancet Psychiatry,2022

2. Household economic burden and outcomes of patients with schizophrenia after being unlocked and treated in rural China[J];Xu L;Epidemiol Psychiatr Sci,2019

3. Prevalence of mental disorders in China: a cross-sectional epidemiological study[J];Huang Y;Lancet Psychiatry,2019

4. Barkhof E, Meijer CJ, de Sonneville LM Interventions to improve adherence to antipsychotic medication in patients with schizophrenia–a review of the past decade. Eur Psychiatry., Li J, Du H, Dou F et al. A study on the changing trend and influencing factors of hospitalization costs of schizophrenia in economically underdeveloped areas of China. Schizophrenia (Heidelb). 2023;9(1):4. doi: 10.1038/s41537-023-00331-6.

5. Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and meta-analysis;Semahegn A;Syst Rev,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3